Hypercholesterolemia - Pipeline Review, H2 2015

Date: December 9, 2015
Pages: 236
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: H807BC988B3EN
Leaflet:

Download PDF Leaflet

Hypercholesterolemia - Pipeline Review, H2 2015
Hypercholesterolemia - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Hypercholesterolemia - Pipeline Review, H2 2015’, provides an overview of the Hypercholesterolemia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hypercholesterolemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypercholesterolemia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Hypercholesterolemia
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Hypercholesterolemia and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Hypercholesterolemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Hypercholesterolemia pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Hypercholesterolemia
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Hypercholesterolemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Hypercholesterolemia Overview
Therapeutics Development
Pipeline Products for Hypercholesterolemia - Overview
Pipeline Products for Hypercholesterolemia - Comparative Analysis
Hypercholesterolemia - Therapeutics under Development by Companies
Hypercholesterolemia - Therapeutics under Investigation by Universities/Institutes
Hypercholesterolemia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Hypercholesterolemia - Products under Development by Companies
Hypercholesterolemia - Products under Investigation by Universities/Institutes
Hypercholesterolemia - Companies Involved in Therapeutics Development
3SBIO INC.
Abeome Corporation
Aegerion Pharmaceuticals, Inc.
Amgen Inc.
AtheroNova Inc.
BioLingus AG
Catabasis Pharmaceuticals, Inc.
Cerenis Therapeutics Holding SA
CymaBay Therapeutics, Inc.
Daewon Pharm Co. Ltd.
DreamPharma Corp.
Dybly AG
Eli Lilly and Company
Esperion Therapeutics, Inc.
F. Hoffmann-La Roche Ltd.
Gemphire Therapeutics Inc.
Hanmi Pharmaceuticals, Co. Ltd.
Immune Response BioPharma, Inc.
Johnson & Johnson
Kadmon Corporation, LLC
Kowa Company, Ltd.
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Regeneron Pharmaceuticals, Inc.
RegenxBio Inc.
Sanofi
Serometrix, LLC
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
The Medicines Company
Thetis Pharmaceuticals LLC
Viking Therapeutics, Inc.
Zhejiang Hisun Pharmaceutical Co., Ltd.
Hypercholesterolemia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(aspirin + lisinopril + lovastatin) - Drug Profile
(atorvastatin calcium + TP-452) - Drug Profile
(bempedoic acid + ezetimibe) - Drug Profile
(ezetimibe + atorvastatin calcium) - Drug Profile
(ezetimibe + rosuvastatin calcium) - Drug Profile
AEM-28 - Drug Profile
AEM-2802 - Drug Profile
AEM-2814 - Drug Profile
AHRO-001 - Drug Profile
alirocumab - Drug Profile
ALN-PCSsc - Drug Profile
AM-0010 - Drug Profile
anacetrapib - Drug Profile
Antisense Oligonucleotide to Target miR-33 for Cardiovascular Diseases - Drug Profile
Antisense Oligonucleotides to Inhibit ApoB100 for Familial Hypercholesterolemia - Drug Profile
aplexone - Drug Profile
bempedoic acid - Drug Profile
bococizumab - Drug Profile
BSN-272 - Drug Profile
CAT-2000 Series - Drug Profile
CAT-2003 - Drug Profile
CAT-2054 - Drug Profile
CER-001 - Drug Profile
colestilan chloride - Drug Profile
Drugs to Inhibit Sortilin for Hypercholesterolemia - Drug Profile
DW-0929 - Drug Profile
DW-3102 - Drug Profile
DYB-186 - Drug Profile
EGF-AB Fc Variants to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
EP-80317 - Drug Profile
evinacumab - Drug Profile
evolocumab - Drug Profile
fenofibrate - Drug Profile
gemcabene calcium - Drug Profile
Gene Therapy to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
HCP-1305 - Drug Profile
HGP-0816 - Drug Profile
HS-25 - Drug Profile
IR-1002 - Drug Profile
ISIS-APOCIIILRx - Drug Profile
J-17 - Drug Profile
KD-026 - Drug Profile
lomitapide mesylate - Drug Profile
LY-3015014 - Drug Profile
MBX-8025 - Drug Profile
MGL-3196 - Drug Profile
mipomersen sodium - Drug Profile
Monoclonal Antibodies to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
Monoclonal Antibody to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
PCSK-9 - Drug Profile
PF-06678552 - Drug Profile
pitavastatin CR - Drug Profile
pradigastat sodium - Drug Profile
RGX-501 - Drug Profile
Small Molecule for Hypercholesterolemia - Drug Profile
Small Molecule to Inhibit Endothelial Lipase for Hypercholesterolemia - Drug Profile
Small Molecule to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
Small Molecule to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
Small Molecules for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders - Drug Profile
Small Molecules to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
ST-101 - Drug Profile
SX-PCK9 - Drug Profile
Synthetic Peptide to Inhibit PCSK9 for Hypercholesterolemia - Drug Profile
TP-452 - Drug Profile
VK-0214 - Drug Profile
VK-2809 - Drug Profile
volanesorsen sodium - Drug Profile
Hypercholesterolemia - Recent Pipeline Updates
Hypercholesterolemia - Dormant Projects
Hypercholesterolemia - Discontinued Products
Hypercholesterolemia - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Hypercholesterolemia, H2 2015
Number of Products under Development for Hypercholesterolemia - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Development by Companies, H2 2015 (Contd.1)
Number of Products under Development by Companies, H2 2015 (Contd.2)
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd.1)
Products under Development by Companies, H2 2015 (Contd.2)
Products under Development by Companies, H2 2015 (Contd.3)
Products under Development by Companies, H2 2015 (Contd.4)
Products under Investigation by Universities/Institutes, H2 2015
Hypercholesterolemia - Pipeline by 3SBio Inc., H2 2015
Hypercholesterolemia - Pipeline by Abeome Corporation, H2 2015
Hypercholesterolemia - Pipeline by Aegerion Pharmaceuticals, Inc., H2 2015
Hypercholesterolemia - Pipeline by Amgen Inc., H2 2015
Hypercholesterolemia - Pipeline by AtheroNova Inc., H2 2015
Hypercholesterolemia - Pipeline by BioLingus AG, H2 2015
Hypercholesterolemia - Pipeline by Catabasis Pharmaceuticals, Inc., H2 2015
Hypercholesterolemia - Pipeline by Cerenis Therapeutics Holding SA, H2 2015
Hypercholesterolemia - Pipeline by CymaBay Therapeutics, Inc., H2 2015
Hypercholesterolemia - Pipeline by Daewon Pharm Co. Ltd., H2 2015
Hypercholesterolemia - Pipeline by DreamPharma Corp., H2 2015
Hypercholesterolemia - Pipeline by Dybly AG, H2 2015
Hypercholesterolemia - Pipeline by Eli Lilly and Company, H2 2015
Hypercholesterolemia - Pipeline by Esperion Therapeutics, Inc., H2 2015
Hypercholesterolemia - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015
Hypercholesterolemia - Pipeline by Gemphire Therapeutics Inc., H2 2015
Hypercholesterolemia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2015
Hypercholesterolemia - Pipeline by Immune Response BioPharma, Inc., H2 2015
Hypercholesterolemia - Pipeline by Johnson & Johnson, H2 2015
Hypercholesterolemia - Pipeline by Kadmon Corporation, LLC, H2 2015
Hypercholesterolemia - Pipeline by Kowa Company, Ltd., H2 2015
Hypercholesterolemia - Pipeline by Merck & Co., Inc., H2 2015
Hypercholesterolemia - Pipeline by Novartis AG, H2 2015
Hypercholesterolemia - Pipeline by Pfizer Inc., H2 2015
Hypercholesterolemia - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2015
Hypercholesterolemia - Pipeline by RegenxBio Inc., H2 2015
Hypercholesterolemia - Pipeline by Sanofi, H2 2015
Hypercholesterolemia - Pipeline by Serometrix, LLC, H2 2015
Hypercholesterolemia - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H2 2015
Hypercholesterolemia - Pipeline by The Medicines Company, H2 2015
Hypercholesterolemia - Pipeline by Thetis Pharmaceuticals LLC, H2 2015
Hypercholesterolemia - Pipeline by Viking Therapeutics, Inc., H2 2015
Hypercholesterolemia - Pipeline by Zhejiang Hisun Pharmaceutical Co., Ltd., H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Hypercholesterolemia Therapeutics - Recent Pipeline Updates, H2 2015
Hypercholesterolemia - Dormant Projects, H2 2015
Hypercholesterolemia - Dormant Projects (Contd.1), H2 2015
Hypercholesterolemia - Dormant Projects (Contd.2), H2 2015
Hypercholesterolemia - Dormant Projects (Contd.3), H2 2015
Hypercholesterolemia - Dormant Projects (Contd.4), H2 2015
Hypercholesterolemia - Discontinued Products, H2 2015
Hypercholesterolemia - Discontinued Products (Contd.1), H2 2015

LIST OF FIGURES

Number of Products under Development for Hypercholesterolemia, H2 2015
Number of Products under Development for Hypercholesterolemia - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

COMPANIES MENTIONED

3SBio Inc.
Abeome Corporation
Aegerion Pharmaceuticals, Inc.
Amgen Inc.
AtheroNova Inc.
BioLingus AG
Catabasis Pharmaceuticals, Inc.
Cerenis Therapeutics Holding SA
CymaBay Therapeutics, Inc.
Daewon Pharm Co. Ltd.
DreamPharma Corp.
Dybly AG
Eli Lilly and Company
Esperion Therapeutics, Inc.
F. Hoffmann-La Roche Ltd.
Gemphire Therapeutics Inc.
Hanmi Pharmaceuticals, Co. Ltd.
Immune Response BioPharma, Inc.
Johnson & Johnson
Kadmon Corporation, LLC
Kowa Company, Ltd.
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Regeneron Pharmaceuticals, Inc.
RegenxBio Inc.
Sanofi
Serometrix, LLC
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
The Medicines Company
Thetis Pharmaceuticals LLC
Viking Therapeutics, Inc.
Zhejiang Hisun Pharmaceutical Co., Ltd.
Skip to top


Ask Your Question

Hypercholesterolemia - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: